MedPath

IBRANCE

IBRANCE

Approved
DIN Number

02493535

Drug Class

Human

Market Date

Sep 21, 2020

Company
HC

Pfizer Canada Ulc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02493535
AIG Number0157970001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
L01EF01 PALBOCICLIB
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

PALBOCICLIBActive
Strength: 75 MG
Monograph: PALBOCICLIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.